Nadine J McCleary, Sui Zhang, Chao Ma, Fang-Shu Ou, Tiffany M Bainter, Alan P Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Bert H O'Neil, Blase N Polite, Howard S Hochster, James N Atkins, Richard M Goldberg, Kimmie Ng, Robert J Mayer, Charles D Blanke, Eileen M O'Reilly, Charles S Fuchs, Jeffrey A Meyerhardt
BACKGROUND: Little is known about the interaction of comorbidities and age on survival outcomes in colorectal cancer (mCRC), nor how comorbidities impact treatment tolerance. METHODS: We utilized a cohort of 1345 mCRC patients enrolled in CALGB/SWOG 80405, a multicenter phase III trial of fluorouracil/leucovorin + oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) plus bevacizumab, cetuximab or both. Endpoints were overall survival (OS), progression-free survival (PFS), and grade ≥ 3 toxicities assessed using NCI CTCAE v...
May 2022: Journal of Geriatric Oncology